A new compound W026B alleviates ischemic brain injury through inhibiting the production of inflammatory cytokines in pMCAO and tMCAO, and enhances the beneficial effect of tPA

doi:10.5246/jcps.2018.10.069

Abstract

Abstract:

Neruoprotection is considered as one of important therapeutic approaches for ischemic stroke. Inflammation plays an important role in the pathogenesis of ischemic stroke, and the inhibition of inflammation in the ischemic brain tissue may provide neuroprotective effect. In this study, we observed the influence of permanent middle cerebral artery occlussion (pMCAO) and transient MCAO (tMCAO) on NF-κB level and production of several inflammatory cytokines in injured hemisphere in mice, investigated the regulative effect of a new compound W026B on these influences in the two MCAO models. In pMCAO model, 10 μg/kg and 100 μg/kg of W026B (i.v.) significantly reduced infarct volumes, 100 μg/kg of W026B significantly decreased neurologic deficit scores and brain water contents, and 10 μg/kg and 100 μg/kg of W026B reduced Evans blue exudation from ischemic brain tissue. The level of NF-κB was elevated by 17.6 times in injured hemisphere, and the levels of TNF-α, IL-1β and IL-17 were elevated by 2.3 times, 2.2 times and 3.8 times compared with the sham operation group, respectively, 100 μg/kg of W026B significantly reduced these inflammatory cytokines. In tMCAO model, the elevation of NF-κB, TNF-α, IL-1β and IL-17 was 2.3 times, 1.4 times, 1.5 times and 1.4 times compared with the sham operation group, respectively. Moreover, 100 μg/kg of W026B significantly decreased the levels of these inflammatory cytokines. In embolic MCAO mice model, W026B alone significantly reduced infarct volumes, and combined application with tPA further reduced infarct volume. In conclusion, W026B displayed significant protecive effect on three brain ischemia models. It could protect brain against injury induced by ischmia and ischemia-reperfusion through inhibiting the production of NF-κB, TNF-α, IL-1β and IL-17. These results suggest that W026B has a value for further study.

Key words: Ischemia-reperfusion, NF-κB, Proinflammatory cytokines, W026B

CLC Number:

R962

Supporting:

Ye Zhang, Danping Zheng, Mengyang Shui, Ye Liu, Xiaoyan Liu, Yinye Wang. A new compound W026B alleviates ischemic brain injury through inhibiting the production of inflammatory cytokines in pMCAO and tMCAO, and enhances the beneficial effect of tPA[J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(10): 675-685.

References

[1] Turner, R.C.; Dodson, S.C.; Rosen, C.L.; Huber, J.D. The science of cerebral ischemia and the quest for neuroprotection: navigating past failure to future success. J. Neurosurg. 2013, 118, 1072–1085.

[2] O’ollins, V.E.; Macleod, M.R.; Donnan, G.A.; Horky, L.L.; van der Worp, B.H. Howells, D.W. 1026 experimental treatments in acute stroke. Ann. Neurol. 2006, 59, 467–477.

[3] Fu, Y.; Liu, Q.; Anrather, J.; Shi, F.D. Immune interventions in stroke. Nat. Rev. Neurol. 2015, 11, 524–535.

[4] Jin, R.; Yang G.; Li, G. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J. Leukoc. Biol. 2010, 87, 779–789.

[5] Caso, J.R.; Pradillo, J.M.; Hurtado, O.; Lorenzo, P.; Moro, M.A.; Lizasoain I. Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation. 2007, 115, 1599–1608.

[6] Zhang, P.; Liu, X.; Zhu, Y.; Chen, S.; Zhou, D.; Wang, Y. Honokiol inhibits the inflammatory reaction during cerebral ischemia reperfusion by suppressing NF-kappaB activation and cytokine production of glial cells. Neurosci. Lett. 2013, 534, 123–127.

[7] Bu, Q.; Liu, X.; Zhu, Y.; Liu, Y.; Wang, Y. w007B protects brain against ischemia-reperfusion injury in rats through inhibiting inflammation, apoptosis and autophagy. Brain Res. 2014, 1558, 100–108.

[8] Fluri, F.; Schuhmann, M.K.; Kleinschnitz, C. Animal models of ischemic stroke and their application in clinical research. Drug Des. Devel. Ther. 2015, 9, 3445–3454.

[9] Wang, Y.; Liu, Y.; Zhang, P.; Tong, W.; Cai, Y. Magnolol derivatives, honokiol derivatives and their preparation method and application. China, 2013.

[10] Liu, F.; McCullough, L.D. The middle cerebral artery occlusion model of transient focal cerebral ischemia. Methods Mol. Biol. 2014, 1135, 81–93.

[11] Li, H.; Liu X.; Zhu, Y.; Liu, Y.; Wang, Y. Magnolol derivative 002C-3 protects brain against ischemia-reperfusion injury via inhibiting apoptosis and autophagy. Neurosci. Lett. 2015, 588, 178–183.

[12] Ishrat, T.; Mohamed, I.N.; Pillai, B.; Soliman, S.; Fouda, A.Y.; Ergul, A.; El-Remessy, A.B.; Fagan, S.C. Thioredoxin-interacting protein: a novel target for neuroprotection in experimental thromboembolic stroke in mice. Mol. Neurobiol. 2015, 51, 766–778.

[13] Rousselet, E.; Kriz, J.; Seidah, N.G. Mouse model of intraluminal MCAO: cerebral infarct evaluation by cresyl violet staining. J. Vis. Exp. 2012, 6, e4038–e4038.

[14] Cevik, N.G.; Orhan, N.; Yilmaz, C.U.; Arican, N.; Ahishali, B.; Kucuk, M.; Kaya, M.; Toklu, A.S. The effects of hyperbaric air and hyperbaric oxygen on blood-brain barrier integrity in rats. Brain Res. 2013, 1531, 113–121.

[15] Bokhari, F.A.; Shakoori, T.A.; Butt, A.; Ghafoor, F. TNF-alpha: a risk factor for ischemic stroke. J. Ayub Med. Col.l Abbottabad. 2014, 26, 111–114.

[16] Jeong, H.J.; Choi, I.Y.; Kim, M.H.; Kim, H.M.; Moon, P.D.; Hong, J.W.; Kim, S.H. Chungsim-Yeunja-Tang decreases the inflammatory response in peripheral blood mononuclear cells from patients with cerebral infarction through an NF-kappaB dependent mechanism. J. Neuroinflammation. 2010, 7, 85.

[17] Khan, M.M.; Gandhi, C.; Chauhan, N.; Stevens, J.W.; Motto, D.G.; Lentz, S.R.; Chauhan, A.K. Alternatively-spliced extra domain A of fibronectin promotes acute inflammation and brain injury after cerebral ischemia in mice. Stroke J. Cereb. Circul. 2012, 43, 1376–1382.

[18] Chen, B.; Liao, W.Q.; Xu, N.; Xu, H.; Wen, J.Y.; Yu, C.A.; Liu, X.Y.; Li, C.L.; Zhao, S.M.; Campbell, W. Adiponectin protects against cerebral ischemia-reperfusion injury through anti-inflammatory action. Brain Res. 2009, 1273, 129–137.

[19] Watters, O.; O’Connor, J.J. A role for tumor necrosis factor-alpha in ischemia and ischemic preconditioning. J. Neuroinflammation. 2011, 8, 87.

[20] Shaftel, S.S.; Griffin, W.S.; O'Banion, M.K. The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J. Neuroinflammation. 2008, 5, 7.

[21] Li, H.L.; Kostulas, N.; Huang, Y.M.; Xiao, B.G.; van der Meide, P.; Kostulas, V.; Giedraitas, V.; Link, H. IL-17 and IFN-gamma mRNA expression is increased in the brain and systemically after permanent middle cerebral artery occlusion in the rat. J. Neuroimmunol. 2001, 116, 5–14.

[22] Kostulas, N.; Pelidou, S.H.; Kivisakk, P.; Kostulas, V.; Link, H. Increased IL-1beta, IL-8, and IL-17 mRNA expression in blood mononuclear cells observed in a prospective ischemic stroke study. Stroke J. Cereb. Circul. 1999, 30, 2174–2179.

[23] Zhang, J.; Mao, X.; Zhou, T.; Cheng, X.; Lin, Y. IL-17A contributes to brain ischemia reperfusion injury through calpain-TRPC6 pathway in mice. Neuroscience. 2014, 274, 419–428.

[24] Gelderblom, M.; Weymar, A.; Bernreuther, C.; Velden, J.; Arunachalam, P.; Steinbach, K.; Orthey, E.; Arumugam, T.V.; Leypoldt, F.; Simova, O.; Thom, V.; Friese, M.A.; Prinz, I.; Holscher, C.; Glatzel, M.; Korn, T.; Gerloff, C.; Tolosa, E.; Magnus, T. Neutralization of the IL-17 axis diminishes neutrophil invasion and protects from ischemic stroke. Blood. 2012, 120, 3793–3802.